Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

I-SPY Graduates: Where Are They Now?

Jul 11 2016

• By Emily Hayes

tubes

Related Content

Roche’s Master Plan: <em>Perjeta</em> Gains Early Breast Cancer Approval, Late-Stage <em>Kadcyla</em> Data

Oct 07 2013

After ALTTO: I-SPY Will Hold More Clues About pCR Surrogate Endpoint

Jun 09 2014

Failed ALTTO Breast Cancer Trial Casts Doubt On pCR Marker

Jun 02 2014

Life After I-SPY Graduation: Neratinib Likely To Be Tested With Roche’s <em>Perjeta</em>

Apr 22 2014

I-SPY 2 Helping To Normalize Adaptive Trial Designs

Jul 10 2016

Related Companies

AbbVie Inc.

Puma Biotechnology, Inc.

Roche Holding AG

Merck & Co., Inc.

Additional Topics

United States Clinical Trials Regulation Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window